Monopar Therapeutics has initiated a rolling submission of its New Drug Application (NDA) for ALXN1840, a potential treatment for Wilson disease, to the FDA. This allows for a faster review process and, if approved, could introduce the first novel mechanism of action therapy for the condition in decades, potentially granting the company a Priority Review Voucher.
Monopar Therapeutics has begun the rolling submission of its New Drug Application (NDA) for ALXN1840, a drug targeting Wilson disease. This is a significant step towards potential market approval, as a rolling submission allows the FDA to review sections of the application as they are completed, potentially accelerating the overall review timeline. The drug also holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations, with the latter offering the potential for a Priority Review Voucher (PRV) upon approval. A PRV can be sold or used to expedite the review of another drug, representing a valuable asset. This development is a positive catalyst for Monopar, indicating progress towards commercialization and potentially offering a substantial non-dilutive financial asset in the form of a PRV. Short-term, this news could generate investor interest and upward price movement for MNPR; long-term, successful approval and commercialization would be transformative for the company.